| chen, yan yan |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Active, not recruiting | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
|
|
| Not yet recruiting | 3 | 83 | RoW | Nelarabine injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | 12/25 | 05/26 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
| Recruiting | 2 | 80 | RoW | Activated CIK, CIK | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital | Advanced Liver Cancer | 01/21 | 01/21 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Completed | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
NCT05387031: Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease |
|
|
| Recruiting | N/A | 239 | RoW | Ustekinumab, Stelara | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sixth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Soochow University, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Seventh Medical Center of PLA Army General Hospital, First People's Hospital of Hangzhou, Yangzhou University, Xian-Janssen Pharmaceutical Ltd. | Crohn Disease, Stricture; Bowel, Intestinal Stricture | 08/26 | 08/27 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT04390971: Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia |
|
|
| Active, not recruiting | N/A | 3 | RoW | ET-01 | Institute of Hematology & Blood Diseases Hospital, China, EdiGene Inc., The Affiliated Hospital Of Guizhou Medical University, Zunyi Medical College | Transfusion Dependent Beta-Thalassaemia | 06/25 | 08/25 | | |
| Lu, Yinying |
| Recruiting | 2 | 80 | RoW | Activated CIK, CIK | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital | Advanced Liver Cancer | 01/21 | 01/21 | | |
NCT04329429: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 57 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Biliary Tract Cancer | 11/23 | 06/24 | | |
